Compliance might have undone VEST trial of wearable cardioverter-defibrillator

Use of a wearable cardioverter-defibrillator during the first 90 days after myocardial infarction does not provide additional protection against sudden death or death from ventricular tachyarrhythmia compared to usual care. The wearable device was considered as a possible bridge in the immediate post-infarction period to a later implantable-ICD. The multi-national VEST study found 1.6% of ...

Already a member?

Login to keep reading.

© 2021 the limbic